Maryanne Demasi, reports • 1218 implied HN points • 05 Feb 24
- FDA approval of rosuvastatin was based on a flawed trial.
- Rosuvastatin failed to show benefits in reducing heart attacks and strokes.
- Controversy surrounds the JUPITER trial of rosuvastatin for primary prevention.